Literature DB >> 517460

Diagnostic yield of transbronchoscopic biopsies.

R Jenkins, R L Myerowitz, T Kavic, S Slasky.   

Abstract

Transbronchoscopic biopsies of lung (transbronchial) or bronchus (endobronchial) have a high diagnostic of yield when performed by a single expert bronchoscopist or a small group of expert bronchoscopists. This procedure's diagnostic yield was evaluated in a general hospital where biopsies are performed by a diverse group of individuals. One hundred fifty-one consecutive biopsies were reviewed, including 53 transbronchial biopsies and 98 endobronchial biopsies. Only 44% of endobronchial biopsies and 21% of transbronchial biopsies were diagnostic. The diagnostic yield was significantly greater in patients with suspected neoplasms (48%) than in patients with suspected infections (13%). Of 97 patients who ultimately had definitive diagnoses established, 43 (44%) had negative biopsy results, including 36% of those with cancers and 80% of those with infections. Failure to obtain alveolar parenchyma by transbronchial biopsy (probably related to the absence of fluoroscopic control) and failure to obtain multiple tissue fragments during each procedure contributed to the low diagnostic yield. The especially disappointing results of transbronchial biopsy for diagnosis of infection suggest that, in this hospital setting, open lung biopsy may be the procedure of choice when infection is suspected.

Entities:  

Mesh:

Year:  1979        PMID: 517460     DOI: 10.1093/ajcp/72.6.926

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

2.  Comparison of processing techniques for detection of Pneumocystis carinii cysts in open-lung biopsy specimens.

Authors:  J D Gay; T F Smith; D M Ilstrup
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.